The study will enrol adult advanced unresectable or metastatic solid tumour patients. Credit: Colin Behrens from Pixabay.

Enlivex Therapeutics has announced the dosing of the first patient in a Phase I/II clinical trial of Allocetra alone, and along with a PD1 checkpoint inhibitor, in advanced solid tumour patients.

The multicentre, dose escalation, open-label trial has been designed for assessing the tolerability, safety, and preliminary efficacy of the cell therapy and the combination.

Up to 48 subjects with advanced solid tumours are expected to be enrolled in the trial across two stages.

The first stage will investigate escalating Allocetra monotherapy doses administered intravenously (IV) or intraperitoneally (IP) once weekly for three consecutive weeks.

In the second stage, escalating doses of the therapy administered IV or IP and combined with anti-PD1 therapy will be evaluated.

In this stage, patients will be given three Allocetra injections concomitantly with the studied anti-PD1 agent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Assessment of safety and tolerability throughout the treatment period and through one week following the last administration of the therapy is the study’s primary objective.

Efficacy evaluations such as progression-free survival, best overall response rate, and overall survival are the key secondary endpoints.

Variations in immune cell/cytokine profiling in peritoneal fluid will also be evaluated as an exploratory endpoint.

The study will enrol adult advanced, unresectable, or metastatic solid tumour patients.

Tumours in these patients have relapsed or have been refractory to available therapies that have approvals in place.

Subjects not eligible for, or who have declined additional standard-of-care systemic therapy, will also be part of the trial.

Enlivex CEO Oren Hershkovitz said: “Our team is continuing to focus on execution of our strategic and operating plan across our various clinical development verticals, with an ongoing sepsis Phase II clinical trial and two ongoing oncology Phase I/II clinical trials.

“We believe that Allocetra has the potential to provide a paradigm shift in treatment of advanced solid tumours, and we look forward to observing safety and potential indication of effect in patients, who we expect to enrol in our open-label oncology trials during 2023.”

Allocetra is being developed as a universal, off-the-shelf cell therapy.

In August this year, Enlivex received the Israeli Ministry of Health (MOH) approval to commence the Phase I/II clinical trial of Allocetra as a monotherapy, and along with a PD1 checkpoint inhibitor, in patients with advanced solid tumours.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.